Methods of inhibition using glycosyl sulfotransferase-3
View Patent ↗A novel human glycosylsulfotransferase expressed in high endothelial cells (GST-3) and polypeptides related thereto, as well as nucleic acid compositions encoding the same, are provided. The subject polypeptides and nucleic acid find use in a variety of applications, including research, diagnostic, and therapeutic agent screening applications. Also provided are methods of inhibiting selectin mediated binding events and methods of treating disease conditions associated therewith, particularly by administering an inhibitor of at least one of GST-3 or KSGal6ST, or homologues thereof
1. A method for inhibiting a binding event between a selectin and a selectin ligand, said method comprising:
contacting a cell that produces said selectin ligand with an agent that inhibits the sulfation activity of a glycosyl sulfotransferase-3 (GST-3) polypeptide, wherein the GST-3 polypeptide catalyzes the transfer of a sulfate group from a donor compound to a selectin ligand precursor, wherein the GST-3 polypeptide is encoded by a nucleic acid comprising a sequence that is at least 75% identical to the sequence set forth in SEQ ID NO:2, and wherein inhibition of said sulfation activity inhibits a binding event between the selectin and the selectin ligand.
2. The method of claim 1 , wherein the GST-3 polypeptide is encoded by a nucleic acid comprising a sequence that is at least 90% identical to SEQ ID NO:2.
3. The method of claim 1 , wherein the GST-3 polypeptide is encoded by a nucleic acid comprising a sequence that is at least 95% identical to SEQ ID NO:2.
4. The method of claim 1 , wherein the GST-3 polypeptide is encoded by a nucleic acid comprising the nucleotide sequence as set forth in SEQ ID NO:2.
5. The method of claim 1 , wherein the selectin ligand is selected from the group consisting of an L-selectin ligand, a P-selectin ligand, and an E-selectin ligand.
6. The method of claim 1 , wherein the selectin is an L-selectin, and the selectin ligand is an L-selectin ligand.
7. The method of claim 6 , wherein said L-selectin ligand is selected from GlyCAM-1, CD34, MAdCAM-1, Sgp200, and podocalyxin.
8. The method of claim 1 , wherein the cell is a high endothelial cell.
9. The method according to claim 1 , wherein said agent is a small molecule.
10. The method of claim 1 , wherein said agent is an antibody specific for GST-3.
11. The method of claim 10 , wherein said antibody is a polyclonal antibody.
12. The method of claim 10 , wherein said antibody is a monoclonal antibody.
13. A method for inhibiting a binding event between a selectin and a selectin ligand, said method comprising:
contacting a cell that produces said selectin ligand with an agent that inhibits the sulfation activity of a glycosyl sulfotransferase-3 (GST-3) polypeptide, wherein the GST-3 polypeptide catalyzes the transfer of a sulfate group from a donor compound to a selectin ligand precursor, wherein the GST-3 polypeptide comprises an amino acid sequence that is at least 60% identical to the amino acid sequence set forth in SEQ ID NO:1, and wherein inhibition of said sulfation activity inhibits a binding event between the selectin and the selectin ligand.
14. The method of claim 13 , wherein the GST-3 polypeptide comprises the amino acid forth in SEQ ID NO:1.
15. The method of claim 13 , wherein the selectin ligand is selected from an L-selectin ligand, a P-selectin ligand, and an E-selectin ligand.
16. The method of claim 13 , wherein the selectin is an L-selectin, and the selectin ligand is an L-selectin ligand.
17. The method of claim 16 , wherein said L-selectin ligand is selected from GlyCAM-1, CD34, MAdCAM-1, Sgp200, and podocalyxin.
18. The method of claim 13 , wherein the cell is a high endothelial cell.
19. The method of claim 13 , wherein said agent is a small molecule.
20. The method of claim 13 , wherein said agent is an antibody specific for GST-3.
21. The method of claim 20 , wherein said antibody is a polyclonal antibody.
22. The method of claim 20 , wherein said antibody is a monoclonal antibody.
23. A method for inhibiting a binding event between a selectin and a selectin ligand, said method comprising:
contacting a glycosyl sulfotransferase-3 (GST-3) polypeptide with an agent that inhibits sulfation activity of the GST-3 polypeptide, wherein the GST-3 polypeptide catalyzes the transfer of a sulfate group from a donor compound to a selectin ligand precursor, wherein the GST-3 polypeptide comprises an amino acid sequence that is at least 60% identical to the sequence set forth in SEQ ID NO:1, and wherein inhibition of said sulfation activity inhibits a binding event between the selectin and the selectin ligand.
24. The method of claim 23 , wherein the GST-3 polypeptide comprises the amino acid sequence as set forth in SEQ ID NO:1.
25. The method of claim 23 , wherein said amino acid sequence is encoded by a nucleic acid comprising a nucleotide sequence that is at least 75% identical to SEQ ID NO:2.
26. The method of claim 23 , wherein said amino acid sequence is encoded by a nucleic acid comprising a nucleotide sequence that is at least 90% identical to SEQ ID NO:2.
27. The method of claim 23 , wherein said amino acid sequence is encoded by a nucleic acid comprising a nucleotide sequence that is at least 95% identical to SEQ ID NO:2.
28. The method of claim 23 , wherein the GST-3 polypeptide is encoded by a nucleic acid comprising the nucleotide sequence as set forth in SEQ ID NO:2.
29. The method of claim 23 , wherein the selectin ligand is selected from the group consisting of an L-selectin ligand, a P-selectin ligand, and an E-selectin ligand.
30. The method of claim 23 , wherein the selectin is an L-selectin, and the selectin ligand is an L-selectin ligand.
31. The method of claim 30 , wherein said L-selectin ligand is selected from GlyCAM-1, CD34, MAdCAM-1, Sgp200, and podocalyxin.
32. The method according to claim 23 , wherein said agent is a small molecule.
33. The method of claim 23 , wherein said agent is an antibody specific for GST-3.
34. The method of claim 33 , wherein said antibody is a polyclonal antibody.
35. The method of claim 33 , wherein said antibody is a monoclonal antibody.